# Post-Operative Oliguria (Enhanced Evidence-Based Protocol, 2025)

---

## I. Definition & Goals

* **KDIGO definition (gold standard):** urine output (UO) < **0.5 mL/kg/hr for ≥ 6 hours**.
* **Refined thresholds:** UO < **0.3 mL/kg/hr** may better predict post-op AKI in high-risk patients.
* **Obese patients:** Use **ideal body weight (IBW)** for calculation.

  * IBW (men) = height (cm) – 100.
  * IBW (women) = height (cm) – 110.
* **Goal:** Maintain UO ≥ **0.5–1 mL/kg/hr**, individualized.

---

## II. First-Principles Framework

* **Pre-renal (Tank/Pipes):** hypovolemia, bleeding, sepsis/vasodilation, low EABV, **inadequate pre-op optimization (PrevAKI, BigpAK trials)**.
* **Intra-renal (Parenchymal):** ischemic ATN, nephrotoxins, rhabdo, AIN, **pneumoperitoneum-induced renal hypoperfusion** after laparoscopy.
* **Post-renal (Obstruction):** Foley obstruction, clots, retention/BPH, ureteral obstruction; **intra-abdominal hypertension/ACS** (bladder pressure ≥20 mmHg + organ dysfunction).

---

## III. Stepwise Evaluation

### Step 1 — Verify & Check the Line

* Confirm I/Os, review hourly charting.
* Inspect Foley for kinks/loops; flush or replace if obstructed.
* **Bladder scan:** > **200–300 mL** in post-op patients = significant → treat as retention.

### Step 2 — Advanced Bedside Assessment

* Vitals, MAP (≥65), mentation, perfusion exam.
* **POCUS with VExUS:** distinguishes hypovolemia vs venous congestion.
* If tense abdomen/vent pressures rising: measure **bladder pressure**.

  * IAH ≥12 mmHg, ACS ≥20 mmHg with organ dysfunction.

### Step 3 — Focused Workup

* **Labs:** CBC, BMP, Cr, K, Mg/Phos, lactate, CK, UA ± microscopy.
* **Biomarkers:** NGAL, TIMP-2\*IGFBP7 (if available) detect injury earlier than Cr.
* **Indices:**

  * **FENa:** best in oliguric pts without diuretics/CKD (<1% = pre-renal, >2% = ATN).
  * **FEUrea:** <35% = pre-renal, more reliable with diuretic use.
* **Imaging:** renal/bladder US if obstruction suspected.

---

## IV. Stepwise Management

### A. Fix the Easy Stuff First

* Ensure Foley patency or replace.
* Stop nephrotoxins (NSAIDs, ACEi/ARB, aminoglycosides); delay contrast if possible.
* Adjust dosing of renally cleared meds.

### B. Fluid & Hemodynamic Strategy

* **Balanced crystalloids first-line** (LR, Plasma-Lyte). Large RCTs show improved outcomes vs saline without increased hyperkalemia.
* **Goal-directed fluids:** 500–1000 mL bolus with reassessment (MAP, UO, POCUS). Avoid rigid restriction (**RELIEF trial**: restrictive fluids ↑ AKI risk).
* **Sepsis bundle:** \~30 mL/kg crystalloid within 3h if septic, guided by dynamics.
* **Pressors:** Norepinephrine first-line (MAP ≥65). Add vasopressin if NE >15 µg/min.
* **Avoid dopamine** (no renal benefit, potential harm).

### C. If Volume Overloaded / Cardiorenal

* Loop diuretic trial (furosemide 20–40 mg IV; higher if CKD).
* **Furosemide Stress Test (FST):**

  * Timing: within 24–48h of AKI.
  * Dose: 1 mg/kg IV (1.5–2 mg/kg if chronic loop use).
  * **UO <200 mL in 2h = predicts progression** → early nephrology + RRT planning.

### D. Treat Post-Renal Causes

* Retention/clots: large-bore Foley, irrigation/continuous bladder irrigation.
* Upper tract obstruction: renal US/CT + urgent urology (stent/nephrostomy).

### E. Intra-Abdominal Hypertension / ACS

* **IAH:** IAP ≥12 mmHg; **ACS:** IAP ≥20 mmHg with organ dysfunction.
* **Medical management first:** NG/rectal tube decompression, sedation/NMB, judicious fluids, diuresis.
* **Surgery:** decompression if refractory ACS persists.

### F. Dialysis / KRT

* **Indications (AEIOU):** Acidosis, Electrolyte (K+), Ingestions, Overload, Uremia.
* **Timing:** Early initiation does **not** improve mortality vs standard triggers → follow standard indications.
* **CRRT preferred** if unstable.

---

## V. Red Flags — Escalate Immediately

* **UO <0.5 mL/kg/hr × 6h** → immediate eval + FST consideration.
* **UO <0.3 mL/kg/hr × 12h** → nephrology consult mandatory.
* **Anuria ≥6h** or rapid Cr rise → ICU escalation.
* Hypotension/sepsis with oliguria despite resuscitation.
* ACS with IAP ≥20 mmHg and organ dysfunction.
* Pulmonary edema, refractory hypoxemia.
* Persistent obstruction not relieved.

---

## VI. Care Bundles & QI

* **KDIGO AKI bundle:** maintain MAP ≥65, avoid nephrotoxins, monitor Cr/UO closely, maintain normoglycemia (<180 mg/dL), structured fluid plans.
* **ERAS considerations:** Do not over-restrict fluids—periop oliguria still ↑ AKI risk.
* **E-alerts & AKI response teams:** improve adherence, reduce nephrotoxin use, ↑ early nephrology involvement.

---

## VII. Intern Pearls

* **Check the Foley first.**
* Use **VExUS/POCUS** to separate hypovolemia from venous congestion.
* **FENa unreliable** in diuretics/CKD → use FEUrea.
* **FST** is a powerful bedside prognostic tool.
* Avoid HES (hydroxyethyl starch) for resuscitation → renal harm.

---

## VIII. References

* KDIGO AKI Guideline, 2012 (current standard).
* **PrevAKI & BigpAK trials** – perioperative risk optimization.
* **RELIEF Trial, 2018** – restrictive vs liberal fluid therapy.
* **Furosemide Stress Test studies** – predictive tool for AKI progression.
* **WSACS Consensus, 2021** – intra-abdominal hypertension & ACS.
* Tallarico R, McCoy IE, Dépret F, Legrand M. *Perioperative Oliguria.* Anesthesiology, 2024.

---

## Key Takeaways

* **Oliguria = hypoperfusion or obstruction until proven otherwise.**
* Refine thresholds: **<0.3 mL/kg/hr** is more predictive in high-risk surgical patients.
* Always **verify Foley and scan bladder first.**
* Prefer **balanced crystalloids**, avoid excessive restriction.
* **FST, biomarkers, and POCUS** improve risk stratification.
* **Call senior/nephrology early** for persistent oliguria or red flags.
